Mizutani N, Miyazu M, Maehara M, Isomura S, Watanabe K, Imanishi J
Tohoku J Exp Med. 1985 Jul;146(3):277-84. doi: 10.1620/tjem.146.277.
In five patients with subacute sclerosing panencephalitis (SSPE), human leukocyte interferon (IFN) therapy was tried. IFN was administered intramuscularly, intravenously, and intrathecally. The total dose of administered IFN ranged from 13 X 10(6) to 116.92 X 10(6) IU. There were no severe side effects except for temporary high fever and vomiting. Observation of the clinical course were made for 26-60 months. At the beginning of the treatment, one of the patients was at the first stage of Jabbour's classification and the other four at the second stage. No clinical improvement was observed and the clinical course was progressive in all patients. At present, one of the patients was at the second stage and the other four were at the fourth stage. EEGs showed progressive deterioration, and cranial CT scan demonstrated progressive cortical atrophy and ventricular enlargement. Measles antibody titers in the serum and CSF also unchanged. On the other hand, permeability of IFN at blood-brain barrier (BBB) was relatively good.
对5例亚急性硬化性全脑炎（SSPE）患者尝试了人白细胞干扰素（IFN）治疗。IFN通过肌肉注射、静脉注射和鞘内注射给药。给予的IFN总剂量为13×10⁶至116.92×10⁶国际单位。除了短暂的高烧和呕吐外，没有严重的副作用。对临床病程进行了26至60个月的观察。治疗开始时，1例患者处于贾布尔分类的第一阶段，其他4例处于第二阶段。所有患者均未观察到临床改善，临床病程呈进行性发展。目前，1例患者处于第二阶段，其他4例处于第四阶段。脑电图显示进行性恶化，头颅CT扫描显示进行性皮质萎缩和脑室扩大。血清和脑脊液中的麻疹抗体滴度也没有变化。另一方面，IFN在血脑屏障（BBB）的通透性相对较好。
